Umecrine Cognition AB

Umecrine Cognition was founded as a subsidiary to Umecrine AB. Umecrine Cognition is developing pharmaceuticals against neurological disorders in the central nervous system, CNS that are caused by endogenous CNS-active steroids (GABA-steroids). Furthermore, is company active in development and commercialization of novel therapeutics to treat Hepatic Encephalopathy (HE) in patients with liver disease, a growing area with high unmet medical need. HE is a neurocognitive and neuropsychiatric complication, characterized by impaired cognitive and motor functions with symptoms ranging from disorientation through coma. We are developing pharmaceuticals to treat acute life-threatening HE and long-term maintenance in minimal HE caused by endogenous GABA-steroids.


Contact: Magnus Doverskog, CEO

Contact details
Karolinska Institutet Science Park, Fogdevreten 2, SE-171 65 Solna, Sweden
Phone: +468524 - 844 84